Some of the major participants in the antidiabetics market share include Novo Nordisk, AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Halozyme Therapeutics, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Oramed Pharmaceuticals Inc., Pfizer, Sanofi and Takeda Pharmaceutical.

Onglyza belongs to a class of diabetes medications called DPP-4 inhibitors, FDA clinical trial data shows there may be a risk of death for some patients.